Citadel Advisors’s NanoViricides NNVC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $32.7K | Buy |
35,900
+10,700
| +42% | +$11.2K | ﹤0.01% | 12546 |
|
|
2025
Q4 | $28.5K | Sell |
25,200
-12,100
| -32% | -$17K | ﹤0.01% | 12239 |
|
|
2025
Q3 | $53.3K | Sell |
37,300
-5,600
| -13% | -$8.38K | ﹤0.01% | 12162 |
|
|
2025
Q2 | $60.1K | Sell |
42,900
-8,000
| -16% | -$10.9K | ﹤0.01% | 11678 |
|
|
2025
Q1 | $59.6K | Buy |
50,900
+21,300
| +72% | +$27K | ﹤0.01% | 12120 |
|
|
2024
Q4 | $42.3K | Buy |
29,600
+8,400
| +40% | +$12.1K | ﹤0.01% | 12559 |
|
|
2024
Q3 | $31.8K | Buy |
+21,200
| New | +$39.4K | ﹤0.01% | 12374 |
|
|
2024
Q2 | – | Sell |
-24,200
| Closed | -$28.1K | – | 15026 |
|
|
2024
Q1 | $28.1K | Sell |
24,200
-300
| -1% | -$344 | ﹤0.01% | 12752 |
|
|
2023
Q4 | $25K | Buy |
24,500
+10,600
| +76% | +$12.3K | ﹤0.01% | 12431 |
|
|
2023
Q3 | $18.6K | Buy |
+13,900
| New | +$19.7K | ﹤0.01% | 12685 |
|
|
2023
Q2 | – | Sell |
-4,200
| Closed | -$4.92K | – | 14950 |
|
|
2023
Q1 | $4.92K | Sell |
4,200
-256,100
| -98% | -$346K | ﹤0.01% | 13916 |
|
|
2022
Q4 | $289K | Sell |
260,300
-11,700
| -4% | -$18.2K | ﹤0.01% | 9400 |
|
|
2022
Q3 | $471K | Buy |
+272,000
| New | +$593K | ﹤0.01% | 8586 |
|
|
2022
Q2 | – | Sell |
-12,700
| Closed | -$27K | – | 13700 |
|
|
2022
Q1 | $27K | Buy |
12,700
+1,000
| +9% | +$2.34K | ﹤0.01% | 13152 |
|
|
2021
Q4 | $44K | Sell |
11,700
-29,500
| -72% | -$134K | ﹤0.01% | 13316 |
|
|
2021
Q3 | $191K | Buy |
41,200
+5,300
| +15% | +$22.1K | ﹤0.01% | 12047 |
|
|
2021
Q2 | $167K | Buy |
35,900
+15,900
| +80% | +$64.2K | ﹤0.01% | 12387 |
|
|
2021
Q1 | $94K | Sell |
20,000
-1,500
| -7% | -$6.78K | ﹤0.01% | 12520 |
|
|
2020
Q4 | $62K | Sell |
21,500
-9,800
| -31% | -$35.7K | ﹤0.01% | 10484 |
|
|
2020
Q3 | $120K | Buy |
+31,300
| New | +$172K | ﹤0.01% | 9162 |
|
|
2016
Q2 | – | Sell |
-550
| Closed | -$24K | – | 7201 |
|
|
2016
Q1 | $24K | Buy |
550
+500
| +1,000% | +$19.4K | ﹤0.01% | 6426 |
|
|
2015
Q4 | $1K | Buy |
50
+15
| +43% | +$359 | ﹤0.01% | 8619 |
|
|
2015
Q3 | $1K | Buy |
+35
| New | +$926 | ﹤0.01% | 8780 |
|
|
2014
Q4 | – | Sell |
-905
| Closed | -$54K | – | 8648 |
|
|
2014
Q3 | $54K | Buy |
905
+115
| +15% | +$9.03K | ﹤0.01% | 6858 |
|
|
2014
Q2 | $67K | Buy |
+790
| New | +$56.1K | ﹤0.01% | 6534 |
|
Other funds holding NNVC
VCM
MFS
VFT
Citadel Advisors's NNVC Position: Q1 2026 in Review
Citadel Advisors sold out of NanoViricides (NNVC) in Q1 2026, closing a stake of 79,915 shares — an estimated $83.6K sold.
Citadel Advisors first reported a position in NNVC in Q1 2014 and held it in 22 quarters. The position peaked at $143K in Q1 2021. 48 funds tracked by Wall St. Rank hold NNVC as of Q1 2026.
- Citadel Advisors reported no remaining NanoViricides position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 79,915 NanoViricides shares in Q1 2026, an estimated $83.6K.
- Citadel Advisors first reported a position in NanoViricides in Q1 2014 and held it in 22 quarters.
- Citadel Advisors's NanoViricides position peaked at $143K in Q1 2021.
- 48 funds tracked by Wall St. Rank held NanoViricides as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.